Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The current study examined the feasibility of High-Definition tDCS (HD-tDCS) in reducing epileptiform activity in a 30-month-old child suffering from early onset epileptic encephalopathy. HD-tDCS was administered over 10 intervention days spanning two weeks including pre- and post-intervention video-electroencephalography (EEG) monitoring.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT01858285` - Genetics of Epilepsy and Related Disorders

NCT number	NCT02960347
Study type	Interventional
Source	Herzog Hospital
Contact
Status	Completed
Phase	N/A
Start date	February 2016
Completion date	June 2016

Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms